Abstract
Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.
Keywords: Pemetrexed, multi-targeted antifolate, erlotinib, small molecule tyrosine kinase inhibitor (TKI), epidermal growth factor receptor (EGFR), non-small cell lung cancer (NSCLC), Mucosal healing, endoscopy, medical therapy, IBD, Crohn's disease, ulcerative colitis
Current Drug Targets
Title: Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Volume: 11 Issue: 1
Author(s): Tianhong Li, Primo N. Lara Jr., Philip C. Mack, Roman Perez-Soler, David R. Gandara, Gert van Assche, Severine Vermeire and Paul Rutgeerts
Affiliation:
Keywords: Pemetrexed, multi-targeted antifolate, erlotinib, small molecule tyrosine kinase inhibitor (TKI), epidermal growth factor receptor (EGFR), non-small cell lung cancer (NSCLC), Mucosal healing, endoscopy, medical therapy, IBD, Crohn's disease, ulcerative colitis
Abstract: Both the multi-targeted antifolate pemetrexed and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib have established roles in the treatment of advanced non-small cell lung cancer (NSCLC). Given different mechanisms of action and minimal overlapping toxicities, combinations of these agents have been considered. However, four previous phase III trials investigating concurrent chemotherapy with or without EGFR TKIs showed no clinical benefit. Based on preclinical data, we developed a model of pharmacodynamic separation to avoid potential negative interactions between chemotherapy and EGFR TKIs in NSCLC tumors containing wild-type EGFR gene. This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation. Ongoing research efforts investigating this concept are reviewed.
Export Options
About this article
Cite this article as:
Li Tianhong, Lara Jr. N. Primo, Mack C. Philip, Perez-Soler Roman, Gandara R. David, Assche van Gert, Vermeire Severine and Rutgeerts Paul, Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer, Current Drug Targets 2010; 11 (1) . https://dx.doi.org/10.2174/138945010790030983
DOI https://dx.doi.org/10.2174/138945010790030983 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Human Genetic Variation: A Foundation for Rational Diagnosis and Individualized Treatment of Lung Cancer
Current Pharmacogenomics and Personalized Medicine Current and Potential Treatments for Cervical Cancer
Current Cancer Drug Targets T Cell Polarization and the Formation of Immunological Synapses: From Antigen Recognition to Virus Spread
Current Immunology Reviews (Discontinued) Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease
Current Drug Targets Gene Transfer and Drug Delivery with Electric Pulse Generators
Current Drug Metabolism Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine New Insights into Neoangiogenesis and Breast Cancer Development and Progression
Current Angiogenesis (Discontinued) Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews A Review on Lung Cancer Diagnosis Using Data Mining Algorithms
Current Medical Imaging Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Genetics of Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Mass Spectrometric Strategies and Their Applications for Molecular Mass Determination of Recombinant Therapeutic Proteins
Current Pharmaceutical Biotechnology Research Advances of Endostatin and its Short Internal Fragments
Current Protein & Peptide Science Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry